Precision medicine applied to COPD: The beginning of a revolution
Resumen
El desarrollo exponencial en múltiples áreas de la ciencia, desde la genética, pasando por la biología, la química, etc., y terminando con la inteligencia artificial ha creado un nuevo campo en el área de la salud: la medicina de precisión, con la promesa de individualizar el diagnóstico y tratamiento óptimos para cada paciente. Aunque sus avances han sido más notables en el área de la oncología, con resultados impensables hace unos pocos años, el turno le está llegando a la neumología. En este artículo presentamos un resumen sobre al estado de la ciencia en lo que respecta a la medicina de precisión aplicada a la enfermedad pulmonar obstructiva crónica, con énfasis en las distinciones entre pacientes con el mismo diagnóstico clínico, pero con profundas diferencias en su biología a nivel molecular.
Abstract
Recent developments in multiple scientific fields, from genetics, biology, chemistry, and artificial intelligence has created a new area in health care: Precision Medicine, with the promise of individualized and optimal diagnosis and treatment for each patient. Although its advances have been more notable in the field of oncology, with results unthinkable a few years ago, it is now Pulmonology’s turn”. In this article, we present a summary of the state of the science regarding precision medicine applied to chronic obstructive pulmonary disease, with emphasis on the distinction between patients with the same clinical diagnosis, but with profound differences at the biomolecular level.
Abstract
Recent developments in multiple scientific fields, from genetics, biology, chemistry, and artificial intelligence has created a new area in health care: Precision Medicine, with the promise of individualized and optimal diagnosis and treatment for each patient. Although its advances have been more notable in the field of oncology, with results unthinkable a few years ago, it is now Pulmonology’s turn”. In this article, we present a summary of the state of the science regarding precision medicine applied to chronic obstructive pulmonary disease, with emphasis on the distinction between patients with the same clinical diagnosis, but with profound differences at the biomolecular level.
Palabras clave:
endotipo, etiotipos, genómica, transcriptómica, proteómica, metabolómicaKeywords:
phenotype, endotype, etiotype, genomics, transcriptonomics, proteomics, metabolomicsReferences
1. Chen S, Kuhn M, Prettner K, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study. Lancet Glob Health. 2023;11(8):e1183-e1193.
2. Agusti A, Faner R. Personalizing COPD care: phenotypes, endotypes, GETomics, the the trajectome, syndemics and treatable traits. Presse Med. 2025:104318.
3. Lowe KE, Regan EA, Anzueto A, et al. COPDGene(®) 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease. Chronic Obstr Pulm Dis. 2019;6(5):384-99.
4. Ishii M. Seeing the Unseen: Cell Population Data Reveal Distinct Inflammatory Phenotypes in Severe COPD. Respirology. 2025.
5. Xie C, Wang K, Yang K, et al. Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits. Respir Res. 2025;26(1):274.
6. Kostikas K, Brindicci C, Patalano F. Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD. Curr Drug Targets. 2018;19(16):1882-96.
7. Cui Y, Chen Y. Blood eosinophils in chronic obstructive pulmonary disease: A potential biomarker. J Transl Int Med. 2023;11(3):193-97.
8. Torres J, Alismail A, Doyle S. The emerging role of biologic therapy in asthma-COPD overlap. Chest Physician. 2025. https://www.chestphysician.org/theemerging-role-of-biologic-therapy-in-asthma-copd-overlap/.
9. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respir Med. 2025;236:107846.
10. Rabe K, Watz H. Heterogeneity of Inflammatory Processes and Pathways Driving Chronic Obstructive Pulmonary Disease. EMJ Reviews. 2024. https://www.emjreviews.com/respiratory/symposium/heterogeneity-of-inflammatory-processes-and-pathways-driving-chronic-obstructive.
11. Blood Eosinophils as a Biomarker in Patients with COPD. Sanofi Campus. 2025. https://pro.campus.sanofi/copd/articles/bloodeosinophils-as-a-biomarker-in-patientswith-copd.
12. Yang HM, Ryu MH, Carey VJ, et al. Chronic Obstructive Pulmonary Disease Exacerbations Increase the Risk of Subsequent Cardiovascular Events: A Longitudinal Analysis of the COPDGene Study. J Am Heart Assoc. 2024;13(11):e033882.
13. Ellingsen J, Janson C, Bröms K, et al. Clinical phenotypes predict exacerbations of COPD: the TIE cohort study. Respir Med. 2025;244:108182.
14. Hernandez P, Bossé Y, Bush P, et al. Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline. Chest. 2025;167(4):1044-63.
15. Brantly ML, Lascano JE, Shahmohammadi A. Intravenous Alpha-1 Antitrypsin Therapy for Alpha-1 Antitrypsin Deficiency: The Current State of the Evidence. Chronic Obstr Pulm Dis. 2018;6(1):100-14.
16. Agusti A, Faner R, Celli B, Rodriguez-Roisin R. Precision medicine in COPD exacerbations. Lancet Respir Med. 2018;6(9):657-9.
17. Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023;61(4).
18. Hopkinson NS, Bush A, Allinson JP, Faner R, Zar HJ, Agustí A. Early Life Exposures and the Development of Chronic Obstructive Pulmonary Disease across the Life Course. Am J Respir Crit Care Med. 2024;210(5):572-80.
19. Clutterbuck EJ, Hirst EM, Sanderson CJ. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood. 1989;73(6):1504-12.
20. Takamoto M, Sugane K. Synergism of IL-3, IL-5, and GM-CSF on eosinophil differentiation and its application for an assay of murine IL-5 as an eosinophil differentiation factor. Immunol Lett. 1995;45(1-2):43-6.
21. Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation. Immunity. 2019;50(4):796-811.
22. Higham A, Beech A, Singh D. The relevance of eosinophils in chronic obstructive pulmonary disease: inflammation, microbiome, and clinical outcomes. J Leukoc Biol. 2024;116(5):927-46.
23. Singh D, Agusti A, Martinez FJ, et al. Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. Am J Respir Crit Care Med. 2022;206(1):17-24.
24. Vanetti M, Visca D, Ardesi F, Zappa M, Pignatti P, Spanevello A. Eosinophils in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2025;19:17534666251335800.
25. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335-49.
26. Negewo NA, McDonald VM, Baines KJ, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1495-504.
27. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130(3):647-654.e610.
28. Celli B. Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details! Arch Bronconeumol. 2017;53(8):415-16.
29. Christenson SA, Hanania NA, Bhatt SP, et al. Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 2025;13(8):687-97.
30. Butler CC, Gillespie D, White P, et al. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. N Engl J Med. 2019;381(2):111-20.
31. Francis NA, Gillespie D, White P, et al. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT. Health Technol Assess. 2020;24(15):1-108.
32. Piggott C, Lyon C. Antibiotics and COPD: Time to order a C-reactive protein test? J Fam Pract. 2021;70(5):244-6.
33. Liu S, Lin Z, You L, et al. Multi-omics identifies severe asthma endotypes linked to Streptococcus dysbiosis and lipid metabolic dysregulation. World Allergy Organ J. 2025;18(11):101132.
34. Kahn P. From genome to proteome: looking at a cell’s proteins. Science. 1995;270(5235):369-70.
35. Cagnone M, Salvini R, Bardoni A, Fumagalli M, Iadarola P, Viglio S. Searching for biomarkers of chronic obstructive pulmonary disease using proteomics: The current state. Electrophoresis. 2019;40(1):151-64.
36. Tang Y, Chen Z, Fang Z, Zhao J, Zhou Y, Tang C. Multi-omics study on biomarker and pathway discovery of chronic obstructive pulmonary disease. J Breath Res. 2021;15(4).
37. Pratte KA, Curtis JL, Kechris K, et al. Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD. Respir Res. 2021;22(1):127.
38. Coxson HO, Dirksen A, Edwards LD, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med. 2013;1(2):129-36.
39. Regan EA, Hersh CP, Castaldi PJ, et al. Omics and the Search for Blood Biomarkers in Chronic Obstructive Pulmonary Disease. Insights from COPDGene. Am J Respir Cell Mol Biol. 2019;61(2):143-9.
40. Fangal VD, Saferali A, Castaldi PJ, Hersh CP, Weiss ST. Distinct physiological, transcriptomic, and imaging characteristics of asthma-COPD overlap compared to asthma and COPD in smokers. EBioMedicine. 2024;110:105453.
41. Li B, Liu J, Cao Y, et al. Multi-omics characterization of early chronic obstructive pulmonary disease. Respir Res. 2025;26(1):167.
42. Kim SH, Ahn HS, Park JS, et al. A Proteomics-Based Analysis of Blood Biomarkers for the Diagnosis of COPD Acute Exacerbation. Int J Chron Obstruct Pulmon Dis. 2021;16:1497-508.
43. Leung JM, Chen V, Hollander Z, et al. COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry. PLoS One. 2016;11(8):e0161129.
44. Serban KA, Pratte KA, Bowler RP. Protein Biomarkers for COPD Outcomes. Chest. 2021;159(6):2244-53.
45. Zhang YH, Castaldi PJ, Bowler RP, et al. Proteomic biomarkers of emphysema-predominant and non-emphysema-predominant chronic obstructive pulmonary disease. EBioMedicine. 2025;117:105800.
46. Crapo JD, Silverman EK. COPDGene. Available from: https://copdgene.org/.
47. Sakornsakolpat P, Prokopenko D, Lamontagne M, et al. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nat Genet. 2019;51(3):494-505.
48. Shrine N, Izquierdo AG, Chen J, et al. Multi-ancestry genome-wide association analyses improve resolution of genes and pathways influencing lung function and chronic obstructive pulmonary disease risk. Nat Genet. 2023;55(3):410-22.
49. Elhusseini ZW, Rafique O, Ryu MH, et al. Molecular Determinants of Lung Function Decline: A Multi-Level Analysis of Gene Expression. Res Sq. 2025.
50. Shrine N, Guyatt AL, Erzurumluoglu AM, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nat Genet. 2019;51(3):481-93.
51. Moll M, Sakornsakolpat P, Shrine N, et al. Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. Lancet Respir Med. 2020;8(7):696-708.
52. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741-50.
53. Zhang C, Konigsberg IR, He Y, et al. MultiTrait Polygenic Scores for COPD and COPD Exacerbations Implicate Druggable Proteins. medRxiv. 2025.
54. Liang Q, Wang Y, Li Z. Comprehensive bioinformatics analysis identifies metabolic and immune-related diagnostic biomarkers shared between diabetes and COPD using multi-omics and machine learning. Front Endocrinol (Lausanne). 2024;15:1475958.
55. Zhu Z, Wang X, Li X, et al. Genetic overlap of chronic obstructive pulmonary disease and cardiovascular disease-related traits: a large-scale genome-wide cross-trait analysis. Respir Res. 2019;20(1):64.
56. Beckonert O, Keun HC, Ebbels TM, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007;2(11):2692-703.
57. Tirelli C, Mira S, Belmonte LA, et al. Exploring the Potential Role of Metabolomics in COPD: A Concise Review. Cells. 2024;13(6).
58. Oliveira GP, de Abreu MG, Pelosi P, Rocco PR. Exogenous Glutamine in Respiratory Diseases: Myth or Reality? Nutrients. 2016;8(2):76.
59. Ubhi BK, Cheng KK, Dong J, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst. 2012;8(12):3125-33.
60. Bowler RP, Jacobson S, Cruickshank C, et al. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. Am J Respir Crit Care Med. 2015;191(3):275-84.
61. Zhou J, Li Q, Liu C, Pang R, Yin Y. Plasma Metabolomics and Lipidomics Reveal Perturbed Metabolites in Different Disease Stages of Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2020;15:553-65.
62. Maniscalco M, Paris D, Melck DJ, et al. Differential diagnosis between newly diagnosed asthma and COPD using exhaled breath condensate metabolomics: a pilot study. Eur Respir J. 2018;51(3).
63. de Laurentiis G, Paris D, Melck D, et al. Separating smoking-related diseases using NMR-based metabolomics of exhaled breath condensate. J Proteome Res. 2013;12(3):1502-11.
64. Polverino F, Mirra D, Yang CX, et al. Similar programmed death ligand 1 (PD-L1) expression profile in patients with mild COPD and lung cancer. Sci Rep. 2022;12(1):22402.
65. Spangenberg SH, Palermo A, Gazaniga NR, et al. Hydroxyproline metabolism enhances IFN-γ-induced PD-L1 expression and inhibits autophagic flux. Cell Chem Biol. 2023;30(9):1115-1134.e1110.
66. Ding HZ, Wang H, Wu D, et al. Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and ‘frequent exacerbator’ phenotype. Mol Med Rep. 2024;30(2).
67. Peng L, You H, Xu MY, et al. A Novel Metabolic Score for Predicting the Acute Exacerbation in Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2023;18:785-95.
68. John J, Burrowes KS, Bhatt SP, et al. Heterogeneity in Normal-Appearing Lung Tissue is Similar Between COPD and Smokers, and Predicts Morbidity and Progression in COPD. Acad Radiol. 2025;32(12):7573-80.
69. Awan HA, Chaudhary MFA, El-Sokkary AD, et al. Association of Lung Quantitative CT Scan Textures With Systemic Inflammation and Mortality in COPD. Chest. 2025;168(5):1107-19.
70. Chaudhary MFA, Hoffman EA, Guo J, et al. Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study. Lancet Digit Health. 2023;5(2):e83-e92.
71. Chaudhary MFA, Awan HA, Gerard SE, et al. Deep Learning Estimation of Small Airway Disease from Inspiratory Chest Computed Tomography: Clinical Validation, Repeatability, and Associations with Adverse Clinical Outcomes in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2025;211(7):1185-95.
72. Curiale AH, Pistenmaa C, San José Estépar R, Díaz AA, Washko G, San José Estépar R. Emphysema progression risk in COPD using a localized foundational model of density evolution. NPJ Digit Med. 2025;8(1):556.
73. Sarwar MR, McDonald VM, Abramson MJ, Paul E, George J. Treatable traits in an English cohort: prevalence and predictors of future decline in lung function and quality of life in COPD. ERJ Open Res. 2021;7(2).
74. Dijk L, Gerritsma YH, Van der Molen T, et al. Treatable Traits in Patients with Obstructive Lung Diseases in a Well-Established Asthma/COPD Service for Primary Care. Int J Chron Obstruct Pulmon Dis. 2025;20:1189-201.
75. Cardoso J, Ferreira AJ, Guimaraes M, Oliveira AS, Simao P, Sucena M. Treatable Traits in COPD A Proposed Approach. Int J Chron Obstruct Pulmon Dis. 2021;16:3167-82.
76. Li S, Yi B, Wang H, Xu X, Yu L. Efficacy and Safety of Biologics Targeting Type 2 Inflammation in COPD: A Systematic Review and Network Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2025;20:2143-59.
77. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. New England Journal of Medicine. 2023;389(3):205-14.
78. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. New England Journal of Medicine. 2024;390(24):2274-83.
79. Hung CT, Hung YC, Suk CW. Comparative Effectiveness of Dupilumab Versus Mepolizumab and Benralizumab in Asthma: A Multinational Retrospective Cohort Study. J Allergy Clin Immunol Pract. 2025;13(7):1707-1716.e1710.
80. Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. 2017;377(17):1613-29.
81. Sciurba FC, Criner GJ, Christenson SA, et al. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. New England Journal of Medicine. 2025;392(17):1710-20.
82. Hong SC, Lee SH. Role of th17 cell and autoimmunity in chronic obstructive pulmonary disease. Immune Netw. 2010;10(4):109-14.
83. Ma R, Su H, Jiao K, Liu J. Association Between IL-17 and Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2023;18:1681-90.
84. Bakakos A, Sotiropoulou Z, Anagnostopoulos N, et al. Anti-inflammatory agents for the management of COPD Quo Vadis? Respir Med. 2025;248:108396.
85. Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(1):234-8.
86. Chapman RW, Phillips JE, Hipkin RW, Curran AK, Lundell D, Fine JS. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009;121(1):55-68.
87. Rennard SI, Dale DC, Donohue JF, et al. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;191(9):1001-11.
88. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154-61.
89. Janjua S, Fortescue R, Poole P. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;5(5):Cd002309.
90. Annangi S, Nutalapati S, Sturgill J, Flenaugh E, Foreman M. Eosinophilia and fractional exhaled nitric oxide levels in chronic obstructive lung disease. Thorax. 2022;77(4):351-6.
91. Takayama Y, Ohnishi H, Ogasawara F, Oyama K, Kubota T, Yokoyama A. Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma-COPD overlap. Int J Chron Obstruct Pulmon Dis. 2018;13:2525-32.
92. Agusti A, Barnes N, Cruz AA, et al. Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respir Med. 2021;187:106572.
93. Cazzola M, Hanania NA, Rogliani P. Comorbidities as treatable traits of chronic airway diseases. Respir Med. 2025;248:108333.
94. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017;195(5):557-82.
95. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418-22.
96. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662-71.
97. Shafiek H, Fiorentino F, Merino JL, et al. Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations. PLoS One. 2015;10(9):e0135199.
98. Pinto-Plata VM, Livnat G, Girish M, et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest. 2007;131(1):37-43.
99. Singh S, Verma SK, Kumar S, et al. Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers. Immunol Lett. 2018;196:1-10.
100. Bhatt SP, Agusti A, Bafadhel M, et al. Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2023;208(10):1026-41.
Downloads
License
Copyright (c) 2026 Revista Neumos
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.